[ad_1]
At the time, the European Medicines Agency (EMA) said Thursday that the vaccine was not associated with an overall increased risk of blood clots.
“It just came to our attention then. (…) It seemed to us that if this has happened to a person and there is a period during which it is real, we cannot rule out that it is not related”, Rugilė Pilvinienė, Senior Information Advisor Pharmacovigilance and Poisons Department of IWT, told BNS on Friday.
However, he emphasized that the European Medicines Agency had evaluated data from different countries and found that the AstraZeneca vaccine “did not present an increased risk of thromboembolism.”
Following the EEA announcement that the AstraZeneca vaccine against COVID-19 is safe and effective, vaccination with the vaccine will resume in Lithuania from Friday.
AstraZeneca vaccination in Lithuania has been suspended since Wednesday.
Such a decision was recommended to the Ministry of Health by the State Drug Control Service, which received three reports of blood clots that occurred after vaccination.
A chain of European countries suspended vaccination with the drug last week due to concerns about blood clots in several tens of millions of vaccinated people.
The EEA indicates that the total number of thromboembolic events reported after vaccination is 469, of which 191 are in the European Economic Area.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
